November 23, 2024 02:25 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Third World War has begun:' Ex-Ukraine military commander-in-chief Valery Zaluzhny | UK-India Free Trade Agreement negotiations to resume in early 2024 | UK can arrest Benjamin Netanyahu if he visits country based on ICC warrant | Centre to send over 10,000 additional soldiers to violence-hit Manipur amid fresh violence | Chhattisgarh: 10 Maoists killed during encounter with security forces in Sukma
Dept of Pharma implementing PLI Scheme for Pharma at cost of Rs 15,000 cr
Photo Courtesy: Unsplash

Dept of Pharma implementing PLI Scheme for Pharma at cost of Rs 15,000 cr

| @indiablooms | 02 Aug 2024, 11:57 pm

New Delhi: The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore and scheme tenure up to FY 2027-28, Ministry of Chemicals and Fertilizers informed Lok Sabha on Friday.

The scheme provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years, Union Minister of State for Chemicals and Fertilizers Anupriya Patel informed the Lok Sabha in response to a question.

The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc.

Orphan drugs are those drugs which are used for treatment of rare diseases.

Under the scheme, a total of eight orphan drugs have been approved for manufacturing.

The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:

  1. Nitisinone used for treatment of Hereditary Tyrosinemia Type 1
  2. Nusinersen used for treatment of Spinal Muscular Atrophy
  3. Rufinamide used for treatment of Lennox-Gastaut syndrome.
  4. Sodium Phenyl Butyrate used for treatment of Urea Cycle Disorders
  5. Tiopronin used for Prevention of Cystine Nephrolithiasis
  6. Trientine Hydrochloride used for treatment of Wilson's disease
  7. Eliglustat used for treatment of Gaucher’s disease
  8. Cannabidiol used for treatment of Dravet-Lennox Gastaut syndrome

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.